Hepatobiliary and Surgical Oncology Unit, UNSW Department of Surgery, St George Hospital, Kogarah, Sydney, NSW, 2217, Australia.
J Cancer Res Clin Oncol. 2014 Jun;140(6):1037-45. doi: 10.1007/s00432-014-1633-3. Epub 2014 Mar 21.
In the setting of colorectal cancer, female gender has been associated with superior long-term outcomes. Our aim is to investigate the gender differences for metastatic epithelial neoplasms of the appendix treated by cytoreductive surgery (CS) and intraperitoneal chemotherapy (IPC).
The survival outcomes of patients treated with CS/IPC from 1996 to 2013 at St. George Hospital, Sydney, Australia, for peritoneal metastases of appendiceal origin were retrospectively analysed.
Two hundred and fifty-seven consecutive patients were followed for a median of 35.3 months. Baseline characteristics between genders were comparable, including age (p = 0.13) and peritoneal cancer index (p = 0.94). Median overall survival (OS) and progression-free survival (PFS) was not reached (NR) and 44.4 months, with a 3-, 5- and 10-year survival of 82, 74 and 64 %. OS and PFS for females was NR and 50.7 months, compared to NR (p = 0.007) and 31.5 months for males (p = 0.07). Three-, 5- and 10-year survival rates for females were 88, 84 and 72 % compared to 74, 61 and 53 % for males.
Observed gender differences for neoplasms of the appendix may direct future research in gender-specific tumour markers and the development of adjuvant therapies to improve patient outcomes.
在结直肠癌患者中，女性的长期预后优于男性。我们旨在研究接受细胞减灭术（CS）和腹腔内化疗（IPC）治疗的阑尾转移性上皮肿瘤的性别差异。
回顾性分析了 1996 年至 2013 年期间在澳大利亚悉尼圣乔治医院接受 CS/IPC 治疗的阑尾来源腹膜转移患者的生存结果。
257 例连续患者的中位随访时间为 35.3 个月。性别间的基线特征无差异，包括年龄（p = 0.13）和腹膜癌指数（p = 0.94）。中位总生存期（OS）和无进展生存期（PFS）未达到（NR）和 44.4 个月，3、5 和 10 年生存率分别为 82%、74%和 64%。女性的 OS 和 PFS 为 NR 和 50.7 个月，而男性的 OS 和 PFS 为 NR（p = 0.007）和 31.5 个月（p = 0.07）。女性的 3、5 和 10 年生存率分别为 88%、84%和 72%，而男性的 3、5 和 10 年生存率分别为 74%、61%和 53%。
观察到的阑尾肿瘤性别差异可能指导未来的研究，包括针对特定性别肿瘤标志物的研究和辅助治疗的开发，以改善患者的预后。
